Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Anguilla Tech Gazette.
Press releases published on May 10, 2025
Akero Therapeutics présente les résultats de la 96e semaine de l’essai clinique de phase 2b SYMMETRY sur l’éfruxifermine chez des patients atteints de cirrhose compensée causée par une stéatohépatite associée à un dysfonctionnement métabolique (MASH), …
GlobeNewswire
·
May 10, 2025
SOUTH SAN FRANCISCO, État de Californie, 10 mai 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ : AKRO), une société en phase clinique développant des traitements révolutionnaires pour les patients atteints de maladies métaboliques graves et dont …
Akero Therapeutics annonce la publication de l’essai de phase 2b SYMMETRY dans le New England Journal of Medicine
GlobeNewswire
·
May 10, 2025
Les résultats confirment le bénéfice potentiel de l’éfruxifermine (EFX) pour déclencher une amélioration de la fibrose chez les patients atteints de cirrhose compensée (fibrose F4) due à une MASH ; les données à 96 semaines de l’essai SYMMETRY ont fait l’ …
The Most Potentially Profitable Investment in 2025 Is to Earn Passive Income Every Day Through PAIRMiner Crypto Cloud Mining
GlobeNewswire
·
May 10, 2025
PAIRMiner, a fully regulated cloud mining platform, allows users to mine Bitcoin and other cryptocurrencies without technical expertise or equipment, backed by transparency and ease of use. PAIRMiner Image LOS ANGELES, May 10, 2025 (GLOBE NEWSWIRE) -- …
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
GlobeNewswire
·
May 10, 2025
Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response Data contribute to growing body of support around the anti-fibrotic activity of EFX in patients with pre-cirrhotic MASH SOUTH SAN …
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
GlobeNewswire
·
May 10, 2025
Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress 65% of patients with clinically significant portal hypertension (CSPH) at baseline moved into lower risk …
Best Online Slots Canada 2025 | Best Online Casino In Canada - Nine Casino
GlobeNewswire
·
May 10, 2025
TORONTO, May 10, 2025 (GLOBE NEWSWIRE) -- The growing popularity of Online slots in Canada is exploding, with more and more people logging on to enjoy some high-quality gambling entertainment on the go. Spinning for fun or chasing that huge jackpot has …